Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
Tirzepatide is grabbing attention again. This time, it’s showing serious promise in a tough area: overweight and obese women with polycystic ovary syndrome (PCOS). Researchers in China just ran a 16-week trial, pitting low-dose tirzepatide plus metformin against metformin alone. The results? The combo didn’t just edge out metformin. It crushed it.
Diabetes Obes Metab
by Yang Z, Xu Y, Du H et al.
“Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial. Yang Z(1), Xu Y(1), Du H(2), Liu W(1), Chen H(1), Liu D(1), Zhang L(1), Wang C(1). Author information: (1)Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. (2)Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. AIMS: This study aimed to assess the effects of low-dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS: Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks. The primary outcome was the change in body weight. Secondary outcomes included changes in anthropometric measures other than body weight, body composition, reproductive hormone levels, metabolic and endocrine parameters, inflammatory markers and menstrual cycle regularity. All outcomes were assessed at baseline and week 16. After week 16, participants were switched to MET monotherapy. Barrier contraception was required for 8 weeks and pregnancy outcomes were subsequently evaluated between weeks 25 and 48. RESULTS: After 16 weeks of treatment, compared with the MET group, the COM group resulted in greater reductions in weight (-1.7 ± 2.5 kg vs. -10.4 ± 3.5 kg; p < 0.001), body mass index (BMI) (-0.68 ± 1.82 vs. -4.12 ± 1.37 kg/m2; p < 0.001), visceral adipose tissue (VAT) (-4.67 ± 9.59 vs. -34.13 ± 15.33 cm2; p < 0.001) and reproductive endocrine-metabolic parameters. Menstrual cycle recovery and total pregnancy rate were higher in the COM group than in the MET group (p = 0.013 and p = 0.014, respectively). CONCLUSIONS: In overweight/obese women with PCOS, low-dose tirzepatide combined with MET was associated with greater reductions in body weight and visceral fat, along with improvements in metabolic and reproductive outcomes compared with MET monotherapy. TRIAL REGISTRATION: ChiCTR2400090908; chictr.org.cn. © 2026 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.”
Here’s the punchline: women on tirzepatide plus metformin lost an average of 10.4 kg—about six times more than those on metformin alone. BMI and visceral fat dropped in tandem. Even more, combo therapy dialed up improvements in metabolic markers, reproductive hormones, and menstrual regularity. Pregnancy rates after the trial ended were also higher for the tirzepatide group.
Key takeaways for peptide researchers:
Low-dose tirzepatide (5 mg weekly) plus standard metformin (1000 mg BID) led to major weight and fat loss—over 30 cm² more visceral fat, on average—versus metformin alone
Metabolic, endocrine, and reproductive improvements tracked with the physical changes
More participants in the combined group saw their menstrual cycles normalize—and more got pregnant when contraception was stopped
Why does this matter? PCOS is notoriously stubborn. Tackling weight, insulin resistance, and hormonal imbalances usually means playing whack-a-mole. This trial suggests a single tirzepatide protocol, layered with metformin, can hit all those targets at once.
For researchers eyeing new PCOS strategies, these findings are a green light for more exploration. Curious about sourcing or protocol design? Check the vendor directory for the latest on tirzepatide availability.
Bottom line: Tirzepatide isn’t just about glucose—it’s showing real utility for metabolic and reproductive research, especially in hard-to-treat PCOS cases.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.